<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411762</url>
  </required_header>
  <id_info>
    <org_study_id>0512000905</org_study_id>
    <nct_id>NCT00411762</nct_id>
  </id_info>
  <brief_title>A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma</brief_title>
  <official_title>A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PhytoCeutica</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research project is to determine the amount of capecitabine (Xeloda) which&#xD;
      can be given safely with PHY906 (investigational drug) on a novel schedule. It is also the&#xD;
      aim of this research project to determine what the effects, good and/or bad, are of combining&#xD;
      capecitabine (Xeloda) with PHY906 (investigational drug) in the treatment of advanced&#xD;
      pancreatic cancer.&#xD;
&#xD;
      PHY906 is a powder from plants sold as a health food supplement in the United States. PHY906&#xD;
      has been used in China, Taiwan and other Asian countries as traditional Chinese medicine for&#xD;
      hundreds of years.&#xD;
&#xD;
      The other drug involved in this study, capecitabine is an oral form of chemotherapy already&#xD;
      approved by FDA in the management of colorectal and breast cancer.&#xD;
&#xD;
      Laboratory studies in animal models have shown that the combination of capecitabine and&#xD;
      PHY906 shrinks liver cancer, and a pilot clinical study is currently evaluating this&#xD;
      combination in patients with liver cancer to define the benefit. PHY906 has also shown to&#xD;
      decrease diarrhea related to chemotherapy in a small study performed in patients with colon&#xD;
      cancer treated at the Yale Cancer Center. Our recent laboratory studies have also shown that&#xD;
      the combination of capecitabine and PHY906 also shrink pancreatic tumors in mouse models.&#xD;
      This prompted us to test the combination of capecitabine and PHY906 in patients with advanced&#xD;
      pancreatic cancer to assess the benefit in survival as well as any decrease in side effects,&#xD;
      such as diarrhea caused by capecitabine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Progression Free Survival</measure>
    <time_frame>Up to 100 weeks</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>Up to 100 weeks</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>PHY906 Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHY906 800mg, orally, twice a day for days 1-4 and capecitabine 1500mg/m^2 days 1-7 of a 14-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>PHY906 Administration</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHY906</intervention_name>
    <arm_group_label>PHY906 Administration</arm_group_label>
    <other_name>Traditional Chinese Medicine: Scutellaria baicalensis Georgi, Glycyrrhiza uralensis Fisch., Ziziphus jujuba Mill., and Paeonia lactiflora Pall</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women ≥18 years of age with either a histologic or cytologic diagnosis of&#xD;
             locally advanced or metastatic pancreatic adenocarcinoma. However, patients with other&#xD;
             solid malignancies will be allowed to participate during the dose escalating Phase I&#xD;
             part of the study, who had failed to respond to standard therapy or for which no&#xD;
             standard therapy exists.&#xD;
&#xD;
          -  In the phase I portion, patients may either have had no prior chemotherapy&#xD;
             (chemotherapy naive), or have been refractory to or relapsed from standard&#xD;
             chemotherapy, including capecitabine-based regimens. However, in the phase II portion&#xD;
             of the study, only pancreatic cancer patients with prior gemcitabine therapy will be&#xD;
             eligible. No prior 5-FU/capecitabine chemotherapy will be allowed EXCEPT previous&#xD;
             adjuvant treatment with 5-FU or capecitabine (radiosensitizing dose) with radiation&#xD;
             completed at least 6 weeks prior to study entry.&#xD;
&#xD;
          -  All patients in both the phase I and phase II portions of this study must have at&#xD;
             least one previously unirradiated, unidimensionally measurable lesion by computerized&#xD;
             tomography (CT) or magnetic resonance imaging (MRI) scan of ≥ 20 mm (if conventional&#xD;
             CT scan) or ≥ 10 mm (if spiral CT scan).&#xD;
&#xD;
          -  Patients with biliary or gastro-duodenal obstruction must have drainage or by pass&#xD;
             prior to starting chemotherapy.&#xD;
&#xD;
          -  Patients with adequate hepatic function defined as&#xD;
&#xD;
               -  AST/ALT ≤ 2.5 X ULN;&#xD;
&#xD;
               -  Total Bilirubin ≤ 2.0 XULN;&#xD;
&#xD;
               -  Alkaline Phosphatase ≤ 5 X ULN (in presence of liver metastasis); or&#xD;
&#xD;
               -  Alkaline Phosphatase ≤ 2.5 X ULN (in absence of liver metastasis).&#xD;
&#xD;
          -  Patients should have an adequate renal function as indicated by a serum creatinine&#xD;
             &lt;1.6 mg/dL or calculated creatinine clearance ≥ 50 mL/min. (Calculated by&#xD;
             Cockcroft-Gault equation).&#xD;
&#xD;
          -  Baseline performance status must be Eastern Cooperative Oncology Group (ECOG) 0, 1, or&#xD;
             2.&#xD;
&#xD;
          -  Women patients who are known to be capable of conception should have a negative serum&#xD;
             pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) within 2 weeks of&#xD;
             starting the study; all patients should agree to use adequate non-estrogenic birth&#xD;
             control methods, consistent with the institute's standard form of contraception if&#xD;
             conception is possible during the study.&#xD;
&#xD;
          -  Provide written informed consent prior to screening.&#xD;
&#xD;
          -  Patients with adequate hematologic tests:&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL;&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 10 9/L;&#xD;
&#xD;
               -  Platelet count ≥ 100.0 x 10 9/L;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Any prior palliative radiation therapy (other than used in the adjuvant therapy of&#xD;
             pancreatic cancer &gt; 6 weeks) must have been completed more than 21 days before entry&#xD;
             into the study and evaluable lesions must not have been included in the radiation&#xD;
             portal.&#xD;
&#xD;
          -  Patients with prior capecitabine therapy for pancreatic cancer (Phase II).&#xD;
&#xD;
          -  Patients with active CNS metastases.&#xD;
&#xD;
          -  Patients with known hypersensitivity or a history of marked intolerance to 5-FU are&#xD;
             ineligible.&#xD;
&#xD;
          -  Because cimetidine can decrease the clearance of 5-FU, patients should not enter on&#xD;
             this study until cimetidine is discontinued.&#xD;
&#xD;
          -  Patients should not receive concurrent therapy with either sorivudine or brivudine,&#xD;
             while receiving capecitabine. If a patient has received prior sorivudine or brivudine,&#xD;
             then at least four weeks must elapse before the patient receives capecitabine therapy.&#xD;
&#xD;
          -  Exclude sexually active males unwilling to practice contraception during the study.&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract, inability to swallow&#xD;
             tablets or those who have malabsorption syndrome.&#xD;
&#xD;
          -  Clinically significant cardiac disease not well controlled with medication (e.g.,&#xD;
             congestive heart failure, symptomatic coronary artery disease, and cardiac&#xD;
             arrhythmias) or myocardial infarction within the last 12 months.&#xD;
&#xD;
          -  No concurrent radiotherapy is allowed.&#xD;
&#xD;
          -  Known DPD (dihydropyrimidine dehydrogenase) deficiency.&#xD;
&#xD;
          -  Patients who have received any previous treatment consisting of standard chemotherapy&#xD;
             (gemcitabine in Phase II study; others in Phase I) within 21 days or an&#xD;
             investigational agent (Phase I) within 30 days on study. Toxicity related to the&#xD;
             previous therapy must have resolved prior to study entry.&#xD;
&#xD;
          -  Patients with previous or concurrent malignancy except for inactive non-melanoma skin&#xD;
             cancer and/or in situ carcinoma of the cervix, or other solid tumor treated curatively&#xD;
             and without evidence of recurrence within the last 3 years prior to study entry.&#xD;
&#xD;
          -  Patients taking herbal medicine(s), including supplement(s), are eligible if they&#xD;
             discontinue the herbal medicine(s)/supplement(s) at least 7 days prior to study entry.&#xD;
&#xD;
          -  Known allergy or hypersensitivity to PHY906 or any of the components used in the&#xD;
             PHY906 formulations, or to capecitabine.&#xD;
&#xD;
          -  Serious concurrent medical illness, which would jeopardize the ability of the patient&#xD;
             to receive the chemotherapy program outlined in this protocol with reasonable safety.&#xD;
&#xD;
          -  Patients with active infections requiring intravenous antibiotic therapy are not&#xD;
             eligible until the infection has resolved.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Hochester, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Comprehensive Cancer Center at Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>December 13, 2006</study_first_submitted>
  <study_first_submitted_qc>December 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2006</study_first_posted>
  <results_first_submitted>March 10, 2015</results_first_submitted>
  <results_first_submitted_qc>March 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2015</results_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PHY906 Administration</title>
          <description>PHY906 800mg, orally, twice a day for days 1-4 and capecitabine 1500mg/m^2 days 1-7 of a 14-day cycle&#xD;
Capecitabine&#xD;
PHY906</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PHY906 Administration</title>
          <description>PHY906 800mg, orally, twice a day for days 1-4 and capecitabine 1500mg/m^2 days 1-7 of a 14-day cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="45" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Progression Free Survival</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>Up to 100 weeks</time_frame>
        <population>20 subjects received 2 cycles or more and were evaluated for response</population>
        <group_list>
          <group group_id="O1">
            <title>PHY906 Administration</title>
            <description>PHY906 800mg, twice a day for days 1-4 and capecitabine 1500mg/m^2 days 1-7 of a 14-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression Free Survival</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <population>20 subjects received 2 cycles or more and were evaluated for response</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="0.4" upper_limit="54.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>Up to 100 weeks</time_frame>
        <population>20 subjects received 2 cycles or more and were evaluated for response</population>
        <group_list>
          <group group_id="O1">
            <title>PHY906 Administration</title>
            <description>PHY906 800mg, twice a day for days 1-4 and capecitabine 1500mg/m^2 days 1-7 of a 14-day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <population>20 subjects received 2 cycles or more and were evaluated for response</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" lower_limit="0.4" upper_limit="84.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected through the duration of the study (approximately 4 years)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PHY906 Administration</title>
          <description>PHY906 800mg, twice a day for days 1-4 and capecitabine 1500mg/m^2 days 1-7 of a 14-day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth/taste alternation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hand-Foot Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Electrolytes Imblances</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Liver Function Tests</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Hochster</name_or_title>
      <organization>Yale University</organization>
      <email>Howard.Hochster@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

